



Targeted DNA Demethylation and Endogenous Gene Activation Using Programmable TALE-TET1 Fusions

Citation

Maeder, M. L., J. F. Angstman, M. E. Richardson, S. J. Linder, V. M. Cascio, S. Q. Tsai, Q. H. Ho, et al. 2013. "Targeted DNA Demethylation and Endogenous Gene Activation Using Programmable TALE-TET1 Fusions." *Nature biotechnology* 31 (12): 10.1038/nbt.2726. doi:10.1038/nbt.2726. <http://dx.doi.org/10.1038/nbt.2726>.

Published Version

doi:10.1038/nbt.2726

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406528>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



Published in final edited form as:

Nat Biotechnol. 2013 December ; 31(12): . doi:10.1038/nbt.2726.

Targeted DNA Demethylation and Endogenous Gene Activation Using Programmable TALE-TET1 Fusions

Morgan L Maeder^{1,2,3,#}, James F Angstman^{1,2,4,#}, Marcy E Richardson⁵, Samantha J Linder^{1,2}, Vincent M Cascio^{1,2}, Shengdar Q Tsai^{1,2,6}, Quan H Ho^{1,2}, Jeffrey D Sander^{1,2,6}, Deepak Reyon^{1,2,6}, Bradley E Bernstein^{1,6,7,8}, Joseph F Costello⁹, Miles F Wilkinson^{5,10}, and J Keith Joung^{1,2,3,6,*}

¹Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129 USA

²Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, MA 02129 USA

³Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA 02115 USA

⁴Graduate Program in Molecules, Cells and Organisms, Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138 USA

⁵School of Medicine, Department of Reproductive Medicine, University of California, San Diego, La Jolla, CA 92093-0864 USA

⁶Department of Pathology, Harvard Medical School, Boston, MA 02115 USA

⁷Howard Hughes Medical Institute, Chevy Chase, MD 20815 USA

⁸Broad Institute of Harvard and MIT, Cambridge, MA 02142 USA

⁹Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158 USA

¹⁰Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093

Recent genomewide studies have defined cell type-specific patterns of DNA methylation¹, a modification known to be important for regulating gene expression in both normal development² and disease³ states. However, determining the functional significance of specific methylation events remains a challenging problem due to the lack of targeted methodologies for removing such modifications. Here we describe an approach for efficient targeted demethylation of specific CpGs in human cells using fusions of engineered transcription activator-like effector (TALE) repeat arrays and the TET1 hydroxylase catalytic domain. Using these TALE-TET1 fusions, we demonstrate that modification of certain critical methylated promoter CpG positions can be associated with substantial increases in endogenous human gene expression. Our results delineate a general strategy for understanding the functional significance of specific CpG methylation marks in the context

*To whom correspondence should be addressed: JJOUNG@PARTNERS.ORG.

#These authors contributed equally

Conflict of Interest Statement

M.L.M., J.F.A., and J.K.J. have filed a provisional patent application covering the TALE-TET fusion proteins. J.K.J. has a financial interest in Transposagen Biopharmaceuticals. J.K.J.'s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.

of endogenous gene loci and validate new programmable DNA demethylation reagents with broad potential utility for research and therapeutic applications.

Methylation of DNA at cytosine bases is an important mechanism widely used to regulate gene expression and transposable elements in higher eukaryotic organisms⁴. Regions of hypermethylated DNA in mammalian cells are often associated with silenced, inactive chromatin whereas regions of hypomethylated DNA are often associated with expressed genes and open chromatin^{1,5}. In mammalian cells, the generation of methylated cytosine (5mC) is catalyzed and maintained by DNA methyltransferases (DNMTs) primarily at CpG dinucleotides⁶. One pathway of active 5mC demethylation is initiated by the ten-eleven translocation (TET) family of proteins, enzymes that catalyze the oxidation of 5mC to 5-hydroxymethylcytosine (5hmC), a critical step that appears to be important for ultimate removal of the methyl mark⁷⁻¹³.

Defining the causal effects of specific CpG methylation events has remained challenging due to the lack of targeted methods for converting 5mC to unmethylated cytosine in living cells. Currently, only non-specific approaches exist for removing methyl groups from CpGs. For example, the cytidine analog 5-aza-2'-deoxycytidine (decitabine), an inhibitor of DNMTs, has been widely used to study the effects of demethylation on specific gene promoters. However, decitabine leads to global demethylation of CpGs in cells, making it difficult to definitively establish causal effects. Here we sought to specifically demethylate CpGs in a targeted fashion at endogenous genes by fusing the hydroxylase activity of the human TET1 protein to engineered TALE repeat arrays with programmable DNA-binding specificities. Customized TALE repeat arrays make an attractive platform for directing TET1 activity because monomeric proteins that bind to nearly any target DNA sequence of interest can be robustly made by simple and rapid assembly of individual repeat domains with known single base specificities¹⁴.

In initial experiments, we defined the architecture of a TALE-TET1 fusion protein that could mediate efficient targeted conversion of 5mC to 5hmC at specific CpGs with resulting subsequent demethylation in human cells. To do this, we fused TALE repeat arrays engineered to bind two different sites in the human *KLF4* gene with either full-length human TET1 or its catalytic domain (CD) (Figs. 1a, 1b, 1c; Methods). We then tested whether these four proteins could demethylate CpGs adjacent to the TALE binding sites in human K562 cells using a bisulfite sequencing protocol that utilizes high-throughput next-generation sequencing to generate more than 10,000 sequencing reads per sample (Methods, Supplementary Results, and Supplementary Fig. 1). For both *KLF4* target sites, we found that TALE fusions bearing the TET1 CD domain induced significantly greater decreases in methylation of CpGs proximal to the TALE binding site than those bearing the full-length TET1 protein (Fig. 1d and 1e; Methods). For example, one of the TALE-TET1CD fusion proteins reduced the methylation of CpGs located 10 and 16 bp from the 3' boundary of the TALE binding site by 21% and 30%, respectively, with similar levels of demethylation observed on both DNA strands (Supplementary Fig. 2). Lengthening the linker between the TALE repeat array and the TET1 CD did not appreciably alter demethylation efficiencies observed (Supplementary Fig. 3). Therefore, all subsequent experiments used TALE-TET1CD proteins with a short GGGS linker (hereafter referred to as simply "TALE-TET1" fusion proteins). Control fusion proteins bearing a TALE repeat array targeted to an unrelated *EGFP* reporter gene sequence did not demethylate CpGs in the *KLF4* intron (Figs. 1d and 1e), demonstrating that demethylation requires specific binding to the target locus by the TALE repeats and is not due simply to overexpression of proteins harboring TET1 hydroxylase activity. Based on a dose-response experiment, which showed increased levels of demethylation in cells transfected with greater amounts of plasmid encoding a TALE-

TET1 protein, we identified optimal transfection conditions that maximized both CpG demethylation and cell viability (Supplementary Fig. 4).

We next determined whether TALE-TET1-induced demethylation of CpGs in human promoters might induce expression changes in proximal endogenous genes. The *RHOXF2* / 2B homeobox gene (hereafter referred to as simply *RHOXF2*) is expressed primarily in male germ cells¹⁵. Plasmid-based reporter gene studies using decitabine have demonstrated that *RHOXF2* expression in non-germ cells is strongly repressed by DNA methylation (ref. ¹⁶ and M. Richardson et al., manuscript submitted). We engineered eleven TALE-TET1 proteins (hereafter referred to as RH-1 through RH-11) targeted to sites that lie in close proximity to a total of 18 different CpGs in the *RHOXF2* promoter (Fig. 2a). We transfected plasmids encoding each of these 11 TALE-TET1 proteins into both 293 and HeLa cells and then assayed *RHOXF2* expression and promoter methylation status using quantitative RT-PCR and high-throughput bisulfite sequencing, respectively (Supplementary Fig. 5). We successfully identified three out of six fusions that induced significant demethylation (greater than 15%) at the -250 to +1 region in HeLa and 293 cells and another three out of six that induced significant demethylation (greater than 15%) at the -650 to -850 region in 293 cells. Two of the 11 TALE-TET1 proteins we tested (RH-3 and RH-4) induced high levels of *RHOXF2* mRNA expression in both the 293 and HeLa cell lines and also demethylated proximal CpGs in the -200 to +1 region of the *RHOXF2* promoter (Figs. 2b-2d). The RH-3 fusion also binds to an additional site in the -650 to -850 region of the *RHOXF2* promoter but demethylation of CpGs in this region can only be observed in 293 cells because cytosines in this region are not methylated in HeLa cells (Supplementary Figs. 5 and 6 and data not shown). Interestingly, we found that even greater increases in *RHOXF2* expression could be induced by combined expression of both the RH-3 and RH-4 TALE-TET1 proteins in 293 cells (Supplementary Fig. 7). Although we do not know the mechanism for this dramatic increase, understanding this phenomenon will be an important focus of future studies.

To assess whether the enzymatic activity of the TET1 domain is important for the gene activation observed with the RH-3 and RH-4 proteins, we tested variant fusions bearing mutations (H1671Y, D1673A) known to inactivate TET1 catalytic activity.⁷ We found that these catalytically inactive RH-3 and RH-4 mutants neither demethylated their proximal CpGs nor activated *RHOXF2* gene expression in either 293 or HeLa cells (Figs. 2b, c and e). Western blots also confirmed that the observed inactivity of these RH-3 and RH-4 mutant proteins is not due to their decreased expression in 293 cells (Supplementary Fig. 8). These results strongly suggest that activation of *RHOXF2* expression is mediated by TALE-TET1-induced modification (either hydroxylation and/or demethylation) of specific methylated CpGs in the promoter and not simply by competitive binding of TALE-TET1 fusions with endogenous transcription factors or the presence of a fortuitous transcriptional activation function within the fusion protein.

To further generalize these results, we next sought to demethylate CpGs in an additional locus, the human beta-globin (*HBB*) gene promoter. Previous work has suggested that four CpGs, which are differentially methylated in erythroid cells isolated from fetal liver and adult bone marrow, may play a role in regulating *HBB* gene expression¹⁷. To test this hypothesis, we constructed ten TALE-TET1 proteins targeted to various sites proximal to these four CpGs (Fig. 3a). Although all ten TALE-TET1 fusions (termed HB-1 through HB-10) induced significant demethylation of CpGs near their respective binding sites in human K562 cells (Fig. 3b and 3c), significant increases in *HBB* gene expression as measured by quantitative RT-PCR were observed with only four of these proteins (HB-3, HB-4, HB-5, and HB-6) (Fig. 3d). Of note, the three proteins (HB-4, HB-5, and HB-6) that induced the greatest fold-activation of the promoter were the fusions that induced the

greatest demethylation of the CpG at position –266 (numbered relative to the transcription start site; Fig. 3d). HB-4, HB-5, and HB-6 proteins bearing the H1671Y/D1673A mutations (which inactivate TET1 catalytic domain activity) failed to demethylate the –266 CpG and also failed to efficiently activate *HBB* gene expression in K562 cells (Figs. 3e and 3f). Western blot experiments confirm that the loss of demethylation and gene activation activities observed with the catalytically inactive mutants of HB-5 and HB-6 is not due to decreased protein expression in K562 cells (Supplementary Fig. 9). Furthermore, time-course experiments show that both demethylation of the –266 CpG and activated expression of *HBB* diminish as transfected cells continue to be cultured (Supplementary Results and Supplementary Fig. 10), suggesting that continued expression of TALE-TET1 is required to maintain these effects. Taken together, our findings strongly suggest that either hydroxylation and/or demethylation of this particular methylated CpG is required for the observed activation of *HBB* gene expression.

Our results define a generalizable approach for targeting 5-methylcytosine hydroxylase activity with subsequent cytosine demethylation to any endogenous genomic locus of interest in living cells. While the majority of cytosines that are converted to uracil in our bisulfite experiments are most likely to be unmethylated cytosines, it is possible that a very small percentage of these might also represent 5-formylcytosine (5-fC) or 5-carboxylcytosine (5-caC), further oxidation products of 5-hmC catalyzed by TET1⁹. However, given that 5-fC and 5-caC are rapidly removed from DNA via TDG-mediated excision¹⁸, these oxidation products are likely to be short-lived in our cells. Therefore, we presume that these species will be present at very low levels, as has been previously observed in other mammalian cells⁹.

The TALE-TET1 framework described here can be easily programmed to target essentially any DNA sequence using the simple TALE repeat code and we used this platform to induce locus-specific demethylation at three endogenous genes (*KLF4*, *RHOXF2*, and *HBB*) in three different human cell lines. Although we frequently observed the greatest degree of demethylation within 30 bps of either end of the TALE target binding site, some fusions also induced demethylation of CpGs approximately 150–200 bps away from the target site, suggesting that the TET1-CD might also access regions of open chromatin located at least one nucleosome distance away. In this study, we only examined CpGs proximal to the TALE-TET1 binding site but it is also possible that other sites elsewhere in the genome might also be modified due to higher-order interactions in the three-dimensional structure of nuclear DNA.

Our success rate for making TALE-TET1 fusions capable of modifying methylated cytosines was high but varied by target gene. For the *KLF4* and *HBB* genes, all 12 fusions we made (two at *KLF4* and 10 at *HBB*) induced significant demethylation greater than 15% at CpGs adjacent to their target binding sites; however, for the *RHOXF2* promoter, only ~50% of the fusions we made induced significant demethylation (greater than 15%). The inability of some fusions to mediate significant demethylation might be caused by locus-dependent effects that affect target site occupancy such as chromatin structure, nucleosome occupancy, DNA methylation, or other parameters that could affect DNA-binding by the TALE repeat arrays and/or the efficiency of hydroxylation by the TET1 catalytic domain.

Our experiments provide a framework for using TALE-TET1 proteins to evaluate the functional significance of specific CpG (and possibly non-CpG cytosine) methylation events. In this report, we successfully identified several CpGs within the *RHOXF2* promoter and a single CpG within the *HBB* promoter that, when modified by either hydroxylation and/or demethylation, are associated with an increase in gene expression. Even modest levels of methylated CpG modification in the population of cells can, in some cases, be associated

with high levels of gene activation. We hypothesize that modification of these methylated CpGs might allow endogenous transcription factors present in the 293, HeLa, or K562 cell lines to bind the promoter and activate expression of the endogenous gene. Although the particular CpGs we identified in our transformed cancer cell-based experiments may or may not be involved in normal physiologic regulation of the *RHOXF2* or *HBB* genes, our proof-of-principle experiments nonetheless illustrate a general strategy that could be used in other more physiologically relevant cell types (e.g.—primordial germ or erythroid cells) to define critical methylation events involved in the regulation of these genes. Additionally, our TALE-TET1 fusions should provide important tools for performing other, more detailed mechanistic studies that define how the loss of methylation marks in turn leads to increases in promoter activity (e.g.—by enhancing or reducing the binding of particular transcription factors).

An important and as-yet unanswered issue for future studies will be to define the genome-wide specificities of our TALE-TET1 proteins. All of the proteins we constructed for the *RHOXF2* and *HBB* promoters were designed to bind 20 bp sites, sequences sufficiently long enough to be potentially unique in the human genome. However, although previously published *in vitro* SELEX experiments suggest that monomeric TALE repeat arrays are specific for their intended target sites¹⁹, to our knowledge the genome-wide specificities of such proteins in human cells have not been described. Engineered zinc finger (ZF) proteins might provide a potential alternative to TALE repeat arrays for targeting TET1 activity and at least one published report has suggested that monomeric six-finger proteins can be highly specific in human cells²⁰. We have also engineered multiple six-finger ZF-TET1 fusion proteins targeted to 18 bp sequences in the *KLF4* and *HBB* genes (Supplementary Methods) and demonstrated that these can induce targeted demethylation with efficiencies that appear to be comparable to those induced by TALE-TET1 proteins (Supplementary Results and Supplementary Figs. 11 and 12). Regardless of which platform ultimately proves to be more specific, potential off-target effects can be readily accounted for by constructing and testing multiple targeted TALE-TET1 or ZF-TET1 fusion proteins for each CpG or cluster of CpGs to be demethylated. For example, our finding that three different TALE-TET1 proteins can all demethylate a common CpG and induce changes in *HBB* gene expression strongly suggests that the observed phenotype is due to binding at the intended target sequence and not at an off-target site elsewhere in the genome.

In addition to off-target effects resulting from unintended binding elsewhere in the genome, it is also possible that TALE-TET1 fusions could induce demethylation that is not dependent upon binding by the TALE repeat array portion of the protein. This can be seen in some of our experiments with fusions targeted to an off-target site in the EGFP reporter gene causing some level of non-specific demethylation at endogenous loci (see, for example, Fig. 3c and 3d), presumably caused by non-DNA-bound proteins acting from solution. Until such non-specific effects can be minimized (perhaps by decreasing or controlling the expression level of TALE-TET1 proteins), these results highlight the need to always perform controls with fusions targeted to other sites. These controls will be crucial for interpreting whether phenotypic effects induced by a particular TALE-TET1 protein depend upon the TALE repeat array-mediated sequence-specific localization of TET1 activity

We also do not yet understand why some CpGs are more efficiently demethylated than others by our TALE-TET1 fusions. For example, in our experiments we were able to demethylate some CpGs in the *HBB* locus very efficiently (as high as 84%) whereas other CpGs in the *RHOXF2* locus were less efficiently demethylated (maximum of 42% and 25% in HeLa and 293 cells, respectively). As noted above, this could be partly due to locus-specific effects that affect the DNA-binding and/or hydroxylase activities of the fusions. However, it is also possible that various factors in the cells may be actively re-methylating

CpGs and thus the extent of methylation observed may represent a steady-state between de- and re-methylation. Our time-course results at the *HBB* locus (Supplementary Fig. 10) are consistent with the idea that re-methylation may be occurring in K562 cells because demethylated CpGs appear to become re-methylated as the TALE-TET1 encoding plasmid is lost from the cells. Delineating the parameters that affect the ultimate efficiency of demethylation will be important to further optimize the effects of our TALE-TET1 proteins.

The TALE-TET1 platform described here and other fusions proteins recently described by our group²⁷ and others²⁸ represent novel and important additions to the growing toolbox of reagents for performing targeted editing of epigenomic modifications. Previously described reagents that target histone methyltransferases (SUV39H1 and G9A²¹) or DNA methyltransferases (bacterial enzymes^{22–26} and human DNMT3a and 3b subunits^{27–29}) used engineered zinc finger proteins, which can be more challenging to construct than TALEs. Continued construction and characterization of tools to modify histones and DNA methylation might in the future enable the stable, heritable changes in the expression of any gene of interest. Development of such a capability in the longer-term would enable numerous research applications as well as potential therapeutic strategies for diseases caused by dysregulated gene expression.

Online Methods

TALE-TET1 Fusion Protein Design and Construction

The full TET1 coding sequence was synthesized as gBlocks (Integrated DNA Technologies) and assembled by standard restriction enzyme digest and ligation to construct TET1-FL and TET1-CD expression vectors. All TALEs were assembled using the FLASH method and were cloned into TALE-TET1 expression vectors (pJA344C7, pJA345D4, pJA344E9 and pJA247) containing one of four 0.5 C-terminal TALE repeats, an N-terminal nuclear localization signal, the $\Delta 152$ TALE N-terminal domain and the +95 TALE C-terminal domain as previously described^{19,30}. In all expression plasmids used, either TET1-FL or TET1-CD was fused to the C-terminal end of the TALE-derived DNA-binding domain via a GlyGlyGlySer linker and expression of this fusion was driven by an EF1 α promoter. For the Western blot experiments, expression vectors had an additional triple-FLAG tag cloned upstream of the nuclear localization signal. Sequences of all constructs are shown in Supplementary Fig. 13.

Cell Culture and Transfection

FlpIn-TREx HEK293 (Life Technologies) and HeLa (ATCC) cells were cultured in Advanced DMEM supplemented with 10% FBS, 1% Glutamax, and 1% penicillin-streptomycin (Invitrogen). K562 (ATCC) cells were maintained in RPMI supplemented with 10% FBS, 1% Glutamax, and 1% penicillin-streptomycin. All cell lines were tested for mycoplasma every two weeks. Plasmids encoding TALE-TET1 fusions targeted to the *KLF4* and *HBB* loci were transfected into K562 cells by Nucleofection. Briefly, 10 μ g of TALE-TET1-encoding plasmid (or 2, 5, 10, 20 or 50 μ g in the dose-response experiment) and 500 ng pmaxGFP plasmid were Nucleofected into 1×10^6 K562 cells using Kit V (Lonza) and program T-016. Control transfections used 500 ng pmaxGFP plasmid (Lonza). Fluorescent microscopy was used to ensure consistent and high levels of transfection efficiency in all K562 experiments and FACS analysis showed ~80–90% of transfected cells are GFP+ under these conditions. Plasmids encoding TALE-TET1 fusions targeted to human *RHOXF2* were transfected into 293 or HeLa cells using Lipofectamine LTX according to the manufacturer's instructions (Life Technologies). Briefly, 3.2×10^5 293 cells or 1×10^5 HeLa cells were seeded into 12-well plates and transfected the following day with 1.2 μ g TALE-TET1-encoding plasmid, 60 ng pmaxGFP plasmid, 1 μ l Plus reagent, and

3.3 μ l Lipofectamine LTX. Fluorescent microscopy was used to ensure consistent and high levels of transfection efficiency. Cell viability in K562 cells was assayed by resuspending cells in PBS with 10% FBS and 1 μ g/ml propidium iodide and analyzing by FACS.

Genomic DNA and Total RNA isolation

Four days post-transfection, genomic DNA (gDNA) was isolated using the QIAamp DNA Blood Mini Kit (Qiagen) according to manufacturer's protocol. Total RNA was isolated from cells transfected with plasmids encoding TALE-TET1 fusions targeting *HBB* or *RHOXF2* using the PureLink RNA Mini Kit (Ambion) according to the manufacturer's instructions. RNA was treated with TurboDNA-Free (Ambion).

High-Throughput Bisulfite Sequencing

500 ng of genomic DNA isolated from transfected cells was bisulfite treated using the EZ DNA methylation, EZ DNA Methylation-Gold or EZ DNA Methylation-Lightning Kit (Zymo Research) according to the manufacturer's instructions. All samples underwent bisulfite conversion with an efficiency of at least 98.5% as judged by conversion of unmethylated, non-CpG cytosines. Genomic DNA sites in *KLF4*, *HBB*, and *RHOXF2* were amplified by PCR using bisulfite-converted gDNA as a template with Kapa HiFi HotStart Uracil+ ReadyMix (Kapa Biosystems) (for *KLF4* and *HBB* sites) or Qiagen's PyroMark PCR Kit (for *RHOXF2* sites). Standard Illumina adaptors were added by either ligation or PCR and Illumina multiplex barcodes were added by PCR. For details of PCR reactions, see Supplementary Methods. Pooled amplicons were sequenced using an Illumina MiSeq with 150 bp paired-end reads (Dana Farber MBCF Genomics Core). For each experimental sample assayed, we analyzed between 10,000 and 375,000 reads. Note that because *RHOXF2* and *RHOXF2B* sequences are identical in the region examined, the bisulfite PCR analysis does not distinguish between these two loci. For Sanger sequencing of *KLF4* samples, initial bisulfite PCR products were cloned using the TOPO Zero-Blunt cloning kit (Life Technologies) and transformed into *E. coli*. Plasmid DNA was purified from the resulting colonies and sequenced by the MGH DNA Core facility.

qRT-PCR assays

For assay of *HBB* gene expression, RNA was reverse transcribed using the SuperScript III First-Strand Synthesis SuperMix and oligo-dT (Life Technologies). Quantitative PCR was performed with Taqman Universal PCR Mastermix (Applied Biosystems) on an ABI 7500 Fast Real-Time PCR system with the following primer/probe sets: Forward *HBB* primer 5'-CAAGGGCACCTTTGCCACAC-3'; Reverse *HBB* Primer 5'-TTTGCCAAAGTGATGGGCCA-3'; *HBB* Taqman Probe 5'-/56-FAM/CCTGGGCAA/ZEN/CGTGCTGGTCTGTGT/3IABkFQ/-3'; Forward β -actin (*ACTB*) Primer: 5'-GGCACCCAGCACAATGAAG-3'; Reverse *ACTB* primer 5'-GCCGATCCACACGGAGTACT-3'; *ACTB* Taqman Probe 5'-/5MAX550-Y/TCAAGATCA/ZEN/TTGCTCCTCCTGAGCGC/3IABIk_FQ/-3'.

For assay of *RHOXF2* gene expression, RNA was reverse transcribed using iScript cDNA Synthesis Kit (BioRad) according to manufacturer's protocol. qPCR was performed with SsoAdvanced SYBRGreen Supermix (BioRad) on an ABI StepOnePlus instrument with the following primers: *RHOXF2* Forward primer 5'-GGCAAGAAGCATGAATGTGA-3'; *RHOXF2* Reverse primer 5'-TGTCTCCTCCATTTGGCTCT-3'; M/H Actin Forward primer 5'-GTCCACACCCRCCGCCAG-3'; M/H Actin Reverse primer 5'-CCCACGATGGAGGGGAA-3'. Note that this assay does not distinguish between *RHOXF2* and *RHOXF2B*.

All transfections were performed in triplicate and for each biological replicate at least three technical replicates of the qPCR assay were performed. Statistical significance was determined by comparing experimental samples against the off-target control using a one-sided t-test after confirming that data sets exhibited a normal distribution as determined by a Shapiro-Wilk test for normality ($p < 0.05$). The similarity of variance between groups was determined using an f-test. When variance was equal between data sets, a two-sample equal variance t-test was used and when variance was unequal, a Welch's t-test was used.

Accession Codes

All raw sequenced reads and BSMAP processed data files have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE50761 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50761>) GSE50761.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by a National Institutes of Health (NIH) Director's Pioneer Award DP1 GM105378 (to J.K.J.), NIH P50 HG005550 (to J.K.J.), NIH R01 HD053808 (to M.F.W.), NIH R01 HD045595 (to M.F.W.), NIH R01 CA169316 (to J.F.C.), NIH F32 GM105189 (to S.Q.T.), Defense Advanced Research Projects Agency (DARPA) W911NF-11-2-0056 (to J.K.J.), the Karen Osney Brownstein Endowed Chair (to J.F.C.), the Jim and Ann Orr Massachusetts General Hospital (MGH) Research Scholar Award (to J.K.J.), and a US National Science Foundation Graduate Research Fellowship (to M.L.M.). We thank the MGH Nucleic Acid Quantitation Core (supported by NIH P30 NS45776) for use of their real-time PCR machine.

References

1. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat. Rev. Genet.* 2012; 13:484–492. [PubMed: 22641018]
2. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. *Nat. Rev. Genet.* 2013; 14:204–220. [PubMed: 23400093]
3. Brena RM, Costello JF. Genome-epigenome interactions in cancer. *Hum. Mol. Genet.* 2007; 16 Spec No 1:R96–R105. [PubMed: 17613554]
4. Bird A. DNA methylation patterns and epigenetic memory. *Genes Dev.* 2002; 16:6–21. [PubMed: 11782440]
5. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. *Nat. Rev. Genet.* 2008; 9:465–476. [PubMed: 18463664]
6. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. *Science.* 2001; 293:1089–1093. [PubMed: 11498579]
7. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science.* 2009; 324:930–935. [PubMed: 19372391]
8. Guo JU, Su Y, Zhong C, Ming G-L, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. *Cell.* 2011; 145:423–434. [PubMed: 21496894]
9. Ito S, et al. Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine. *Science.* 2011; 333:1300–1303. [PubMed: 21778364]
10. He YF, et al. Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA. *Science.* 2011; 333:1303–1307. [PubMed: 21817016]
11. Xu Y, et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. *Mol. Cell.* 2011; 42:451–464. [PubMed: 21514197]
12. Williams K, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. *Nature.* 2011; 473:343–348. [PubMed: 21490601]

13. Ito S, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature*. 2010; 466:1129–1133. [PubMed: 20639862]
14. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. *Nat. Rev. Mol. Cell Biol.* 2013; 14:49–55. [PubMed: 23169466]
15. Song HW, et al. The RHOX homeobox gene cluster is selectively expressed in human oocytes and male germ cells. *Hum. Reprod.* 2013
16. Li Q, Bartlett DL, Gorry MC, O'Malley ME, Guo ZS. Three epigenetic drugs up-regulate homeobox gene *Rhox5* in cancer cells through overlapping and distinct molecular mechanisms. *Mol. Pharmacol.* 2009; 76:1072–1081. [PubMed: 19679824]
17. Mabaera R, et al. Developmental- and differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation. *Blood*. 2007; 110:1343–1352. [PubMed: 17456718]
18. Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. *Journal of Biological Chemistry*. 2011; 286:35334–35338. [PubMed: 21862836]
19. Miller JC, et al. A TALE nuclease architecture for efficient genome editing. *Nature Biotechnology*. 2010; 29:143–148.
20. Tan S, et al. Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. *Proc Natl Acad Sci USA*. 2003; 100:11997–12002. [PubMed: 14514889]
21. Snowden AW, Gregory PD, Case CC, Pabo CO. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. *Curr Biol*. 2002; 12:2159–2166. [PubMed: 12498693]
22. Xu GL, Bestor TH. Cytosine methylation targeted to pre-determined sequences. *Nat Genet.* 1997; 17:376–378. [PubMed: 9398832]
23. McNamara AR, Hurd PJ, Smith AEF, Ford KG. Characterisation of site-biased DNA methyltransferases: specificity, affinity and subsite relationships. *Nucleic Acids Res.* 2002; 30:3818–3830. [PubMed: 12202767]
24. Carvin CD, Parr RD, Kladde MP. Site-selective in vivo targeting of cytosine-5 DNA methylation by zinc-finger proteins. *Nucleic Acids Res.* 2003; 31:6493–6501. [PubMed: 14602907]
25. Smith AE, Ford KG. Specific targeting of cytosine methylation to DNA sequences in vivo. *Nucleic Acids Res.* 2007; 35:740–754. [PubMed: 17182629]
26. Nomura W, Barbas CF. In vivo site-specific DNA methylation with a designed sequence-enabled DNA methylase. *J. Am. Chem. Soc.* 2007; 129:8676–8677. [PubMed: 17583340]
27. Li F, et al. Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. *Nucleic Acids Res.* 2007; 35:100–112. [PubMed: 17151075]
28. Rivenbark AG, et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. *Epigenetics*. 2012; 7:350–360. [PubMed: 22419067]
29. Siddique AN, et al. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. *Journal of Molecular Biology*. 2013; 425:479–491. [PubMed: 23220192]
30. Reyon D, et al. FLASH assembly of TALENs for high-throughput genome editing. *Nature Biotechnology*. 2012




Figure 1. TALE-TET1 Fusion Proteins Induce Targeted Demethylation in Human Cells
 (A) Schematic illustrating the predicted domain architecture of the full-length TET1 protein (TET1 FL) and the catalytic domain of the TET1 protein (TET1 CD)⁷. CXXC = CXXC-type zinc-binding domain, NLS = nuclear localization signal, Cys-rich = cysteine-rich region, DSBH = double-stranded β helix domain (DSBH).
 (B) Schematic illustrating general structure of fusions between a TALE repeat array DNA-binding domain and either TET1 FL or TET1 CD.
 (C) Schematic illustrating the human *KLF4* locus with CpGs indicated with black arrows. Red arrows indicate the location and direction (5' to 3') of TALE-TET1 fusion protein

binding sites. Numbering on the bottom line indicates position on the DNA relative to the start site of transcription (right-angle arrow) and numbering on the top line indicates position relative to the beginning of intron 2/3.

(D) Demethylation activities of KL-1 TALE-TET1 CD (top) and KL-1 TALE-TET1 FL (bottom) fusion proteins in human K562 cells. Graphs show the fraction of CpGs methylated (y-axis) for different positions along the length of the second *KLF4* intron (x-axis, numbered relative to the start of the intron). Blue arrow indicates the location and direction (5' to 3') of TALE target binding site. Each point represents the mean of three independent transfection experiments with bars indicating standard errors of the mean. Methylation status for each experiment was assessed using high-throughput bi-sulfite sequencing. Off-target TALE fusions bind to an unrelated sequence in the *EGFP* reporter gene. Note that the GFP control datapoints shown are the same for both graphs and are depicted twice for ease of comparison.

(E) Demethylation activities of KL-2 TALE-TET1 CD (top) and KL-2 TALE-TET1 FL (bottom) fusion proteins in human K562 cells. Same as in (C) but using a TALE repeat array targeted to a second site in the *KLF4* intron.




Figure 2. Targeted demethylation and activation of the human *RHOXF2* gene by TALE-TET1 Fusion Proteins

(A) Schematic illustrating the human *RHOXF2* locus with CpGs indicated with black arrows. Red arrows indicate the location and direction (5' to 3') of 11 TALE-TET1 fusion protein binding sites. Numbering indicates position on the DNA relative to the start site of transcription (right-angle arrow).

(B) Expression levels of *RHOXF2* mRNA (normalized to β -actin mRNA levels) in HeLa cells transfected with plasmids expressing RH-3 or RH-4 TALE-TET1 proteins, RH-3 or RH-4 TALE-TET1 proteins bearing mutations that inactivate TET1 catalytic function, or an off-target TALE-TET1 protein (targeted to *KLF4*) or a control GFP expression plasmid.

Means of three independent samples each assayed three times by quantitative RT-PCR are shown with bars representing standard errors of the mean. Asterisks indicate samples with values significantly greater than those obtained with the off-target control as determined by a one-sided Welch's t-test (n=3, p<0.05).

(C) Expression levels of *RHOXF2* mRNA (normalized to β -actin mRNA levels) in 293 cells transfected with plasmids expressing the indicated TALE-TET1, catalytically inactivated TALE-TET1 or off-target TALE-TET1 fusion protein or a control GFP expression plasmid. Data presented as in (B).

(D) Demethylation activities of RH-3 and RH-4 TALE-TET1 fusion proteins in HeLa (top) and 293 (bottom) cells. Graphs show the fraction of CpGs methylated (y-axis) for different positions along the length of the *RHOXF2* promoter (x-axis, numbered relative to the transcription start site) in cells transfected with plasmids expressing the RH-3, RH-4 (blue), or an off-target (to a site in the *KLF4* gene) TALE-TET1 protein (orange) or GFP (green). Each data point represents the mean of three independent transfection experiments with bars indicating standard errors of the mean. Methylation status for each experiment was assessed using high-throughput bi-sulfite sequencing. Note that the GFP and off-target TALE-TET1 control data points shown are the same in both panels for each cell type and are depicted multiple times only for ease of comparison with experimental samples. Blue arrow indicates the location and direction (5' to 3') of the RH3 or RH4 TALE-TET1 binding sites.

(E) Demethylation activities of catalytically inactive RH-3 and RH-4 TALE-TET1 fusion proteins in HeLa (top) and 293 (bottom) cells. Data represented as in (D) but here showing fraction of CpGs methylated in cells transfected with plasmids expressing RH-3 or RH-4 TALE-TET1 fusions bearing mutations that inactivate TET1 function (red). Note that RH-3, RH-4 and GFP data are the same as in (D) and are depicted again here for ease of comparison with catalytically inactive controls.




Figure 3. Targeted demethylation and activation of the human *HBB* gene by TALE-TET1 Fusion Proteins

(A) Schematic illustrating the human *HBB* locus with CpGs indicated with black arrows. Numbering indicates position on the DNA relative to the start site of transcription (right-angle arrow). Colored arrows indicate the location and direction (5' to 3') of 10 TALE-TET1 fusion protein binding sites.

(B) Demethylation activities of HB-1, -2, -3, -4, -5, and -6 TALE-TET1 fusion proteins in K562 cells. Graphs show the fraction of CpGs methylated (y-axis) for different positions along the length of the *HBB* promoter (x-axis, numbered relative to the transcription start site) in K562 cells transfected with plasmids expressing one of the six HB TALE-TET1

fusion proteins (colored circles), an off-target TALE-TET1 fusion to a site in the *KLF4* gene (black triangles), or GFP (green triangles). Each data point represents the mean of three independent transfection experiments with bars indicating standard errors of the mean. Methylation status for each experiment was assessed using high-throughput bisulfite sequencing. Note that the GFP and off-target TALE-TET1 control data points shown are the same in both panels and are depicted twice for ease of comparison with experimental samples. Colored arrows indicate the location and direction (5' to 3') of the various HB TALE-TET1 binding sites.

(C) Demethylation activities of HB-7, -8, -9, and -10 TALE-TET1 fusion proteins in K562 cells. Data represented as in (B)

(D) Expression levels of *HBB* mRNA (normalized to β -actin mRNA levels) in K562 cells transfected with indicated TALE-TET1 fusion protein expression plasmids or a control GFP expression plasmid. Means of three independent samples assayed by quantitative RT-PCR are shown with bars representing standard errors of the mean. Asterisks indicate samples with values significantly greater than those obtained with an off-target control TALE-TET1 fusion protein (targeted to a site in the human *KLF4* gene) as determined by a one-sided Welch's t-test ($n=3$, $p<0.05$).

(E) Graphs showing the fraction of CpGs methylated (y-axis) for different positions along the length of the *HBB* promoter (x-axis, numbered relative to the transcription start site) in cells transfected with plasmids expressing the HB-4, HB-5 or HB-6 TALE-TET1 fusion, HB-4, HB-5 or HB-6 TALE-TET1 bearing mutations that inactivate TET1 catalytic function, or GFP. Each data point represents the mean of three independent transfection experiments with bars indicating standard errors of the mean. Methylation status for each experiment was assessed using high-throughput bi-sulfite sequencing. Note that the control GFP data shown is the same in all three panels and is depicted multiple times for ease of comparison with experimental samples. Blue arrow indicates the location and direction (5' to 3') of the TALE-TET1 fusion protein binding sites.

(F) Expression levels of *HBB* mRNA (normalized to β -actin mRNA levels) in K562 cells transfected with plasmids expressing HB-4, HB-5 or HB-6 TALE-TET1 fusions, HB-4, HB-5 or HB-6 TALE-TET1 fusions bearing mutations that inactivate TET1 catalytic function, an off-target TALE-TET1 fusion targeted to an unrelated site in the human *KLF4* gene, or GFP. Means of three independent samples assayed by quantitative RT-PCR are shown with bars representing standard errors of the mean. Asterisks indicate samples with values significantly greater than those obtained with the off-target control TALE-TET1 fusion protein as determined by a one-sided, two-sample equal variance t-test ($n=3$, $p<0.05$).